Episode Synopsis "Expanding the Use of Antifibrotic Therapy in Patients with PF"

Listen "Expanding the Use of Antifibrotic Therapy in Patients with PF"

More episodes of the podcast PILOTforPulmonary: 2019 Fall Conference Coverage

• Current Perspective on Antifibrotic Therapy for Patients with IPF
• Nintedanib in Progressive Fibrosing Interstitial Lung Diseases (The INBUILD Trial)
• Goals of Care Across the Disease Continuum in IPF
• Emerging Diagnostic Approaches to Patients with ILD
• Pirfenidone in Patients with Unclassifiable Interstitial Lung Disease
• Considerations for Geriatric ILD Patients
• Nintedanib for Patients with Systemic Sclerosis-Related Interstitial Lung Disease
• Inhaled NO in Patients at Risk for Pulmonary Hypertension Associated with Pulmonary Fibrosis
• Clinical Pearls from New Orleans 2019
• The IPF Cell Atlas
• Senescence, Senolytics, and IPF
• The PRECISIONS Study
• Genomics and Transcriptomics in PF
• Importance of Pulmonary Fibrosis Patient Registries
• Recent Developments in Methodologies to Support the Diagnosis of IPF
• A New Study Evaluating Pulmonary Rehabilitation Added on to Antifibrotic Therapy
• New Developments in Clinical Trials of Pulmonary Fibrosis
• Exploring Antifibrotic Therapy in Patients with Autoimmune-Associated Interstitial Lung Disease
• Exploring Antifibrotic Therapy in Patients with Autoimmune-Associated Interstitial Lung Disease
• Expanding the Use of Antifibrotic Therapy in Patients with PF
• Considerations for the Management of Autoimmune-Related ILD and Chronic Hypersensitivity-Related ILD
• Key Takeaways from Recent Pulmonary Conferences